MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

Key Takeaways Merck shares have risen 9.6% in a month after recovering from a post-earnings dip.Pipeline progress and the Cidara acquisition support momentum.Gardasil weakness, product pressure and Keytruda's 2028 LOE fuel calls for a wait-and-see stance.Merck’s (MRK) shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 inhibitor, Keytruda, missed sales estimates. Merck also narro ...